- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
You are here
Rosette Lidereau, PhD
Department of Tumor Biology
- Seeking to new preventive and treatment strategies for patients with metastatic breast cancer.
- Laboratory studies are ongoing to characterize the role of a protein called Kindlin-1 in breast cancer metastasis.
- These studies may inform preventive approaches that could reduce breast cancer deaths.
Metastatic breast cancer, also called Stage IV, is the most advanced form of breast cancer. While it is treatable, it is incurable and preventing metastasis can save thousands of lives each year. Dr. Lidereau is conducting studies to understand the early processes that lead to metastasis. She has identified a potential target for drug development that would prevent tumors from spreading to other tissues.
Full Research Summary
Dr. Lidereau's BCRF project focuses on understanding the processes involved in metastasis, particularly how tumor cells can migrate, or move from one place to another, a characteristic that normal breast cells do not have.
Her lab uses state-of-the-art technologies to study the role of proteins that control tissue architecture and how they become dysregulated during tumor progression, allowing tumor cell migration. Dr. Lidereau's team has shown that Kindlin-1, a protein that is over-expressed in cancer cells, causes tumor cells to become mobile and increases their ability to invade (break through) neighboring tissue.
Kindlin-1 is a structural protein that interacts with other structural proteins in the cell architecture called integrins. Dr. Lidereau's team is investigating the molecular pathways involved in Kindlin-1/integrin interactions and their effect on migration and invasion of cancer cells.
They recently identified a small protein that blocks the effects of Kindlin-1 and will test whether it can prevent tumor growth in laboratory models of breast cancer.
In related work, Dr. Lidereau’s lab is applying advanced genetic methods to identify changes to DNA that lead to breast cancer metastasis and the potential causes of resistance to treatments.
The studies may lead to new therapeutic strategies for aggressive breast cancers.
Dr. Rosette Lidereau received her PhD in oncology and immunology in 1987 from the Pasteur Institute (working with Chairman and Prof. Barret-Sinoussi) and completed a fellowship in the Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda (Prof. R. Callahan). In 1992, she was recruited by the INSERM (Institut National des Sciences et de la Recherche Médicale), where she served as a Research Director. From 2000, she headed the INSERM Unit U735, a laboratory dedicated to the molecular characterization of breast cancers at the Centre René Huguenin, Saint-Cloud, France.
Dr. Lidereau's scientific career has focused on the biology of breast cancer. Her research interests are the evaluation of oncogenes and the implication of tumor suppressor genes in breast tumorigenesis and their impact in the clinic as prognostic and predictive factors in breast cancer. Her work has been published in peer reviewed journals in which she has authored over 250 scientific articles. She has received several awards including the Henry et Mary-Jane Mitjavile prize from the Academy of Medicine (2005). In addition, she has been actively involved in numerous national and international organizations, including the international TRANSBIG research network and European Union Programmes (framework IV and VI).
Currently she pursues her research activities in the Genetics Laboratory in the Department of Tumor Biology at Institut Curie, Paris. Her investigations focus on the molecular determinants of breast cancer metastasis and their involvement in organ-specificity.